Valbenazine Market: Addressing Tardive Dyskinesia with Targeted VMAT2 Inhibition
The Valbenazine Market is built around valbenazine, a selective inhibitor of vesicular monoamine transporter 2 (VMAT2) indicated for the treatment of tardive dyskinesia (TD). TD is a movement disorder characterized by involuntary, repetitive movements—often of the face, tongue, and extremities—associated with long‑term use of certain antipsychotics and other dopamine‑modulating...
0 Comments
0 Shares